Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of SHR0302 in Hepatic Impairment
NCT04293029Phase 1Completed
- Sponsor
- Hengrui
- Start
- May 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ivarmacitinib (3 arms), sponsored by Hengrui. Primary endpoints: Peak Plasma Concentration, Area under the plasma concentration versus time curve from single dosing time extrapolated to infinity and 1 more. Started May 2020; status: completed.
02
Drugs
ivarmacitinib
Beyond the preview
Go deeper on NCT04293029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04293029.